✦ LIBER ✦

Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer

✍ Scribed by Sherrill, Beth; Di Leo, Angelo; Amonkar, Mayur M.; Wu, Yun; Zvirbule, Zanete; Aziz, Zeba; Bines, Jose; Gomez, Henry L.

Book ID: 121255877
Publisher: Informa plc
Year: 2010
Tongue: English
Weight: 386 KB
Volume: 26
Category: Article
ISSN: 0300-7995
DOI: 10.1185/03007991003590860

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lapatinib plus paclitaxel versus paclita

Lapatinib plus paclitaxel versus paclitaxel alone for first line metastatic breast cancer (MBC) in ErbB2+ patients -Quality of Life (QOL) results

✍ Y. Wu; A. Segreti; D. Cella; A. DiLeo; M. Amonkar; M. Koehler; M. Arbushites; M. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Quality-adjusted survival analysis of fi

Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib

✍ Sherrill, Beth; Sherif, Bintu; Amonkar, Mayur M.; Maltzman, Julie; O’Rourke, Lis 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 497 KB

Quality of life and quality-adjusted sur

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer

✍ Bernhard, J; Zahrieh, D; Zhang, J J; Martinelli, G; Basser, R; Hürny, C; Forbes, 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 192 KB

Quality of life and quality-adjusted sur

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer

✍ Peppercorn, J. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 65 KB

Q-TWiST analysis of ixabepilone in combi

Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer

✍ Patricia K. Corey-Lisle; Ronald Peck; Pralay Mukhopadhyay; Lucinda Orsini; Shima 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB 👁 1 views

A cost-effectiveness analysis of Hercept

A cost-effectiveness analysis of Herceptin® (trastuzumab) in combination with Paclitaxel as a first line treatment for HER2 positive (3+) Metastatic Breast Cancer (MBC) patients in the UK

✍ A. Ratcliffe; C. Poole; D. Miles 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 165 KB